



Matthew H. Mead
Governor

State of Wyoming
Department of Workforce Services
DIVISION OF WORKERS' COMPENSATION

1510 East Pershing Boulevard, South Wing
Cheyenne, Wyoming 82002
<http://www.wyomingworkforce.org>



Joan K. Evans
Director
Lisa M. Osvold
Deputy Director

TOPIC: Buprenorphine (Suboxone) Use

Published by Wyoming Workers' Compensation Medical Case Management Unit

December 18, 2013

Because of requests by physicians, the time limitation of 2 years in opioid dependence was reviewed by the panel on December 18, 2013.

Summary: The use of buprenorphine (Suboxone) for pain will be denied by the Division. Suboxone use is limited to patients with opioid addiction. Approval will be given for one year. Use will be reviewed on an annual basis. Provider will be asked to submit a treatment plan with details about plans to taper the dose as well as information about previous attempts to taper. The goal is to decrease the dose to 8 mg/day or less for patients who require the medication chronically.

August 21, 2013

A Medline search was conducted February 11, 2013, with the focus on use of sublingual buprenorphine and high dose transdermal buprenorphine for chronic pain. Studies including commercially available doses of Butrans were not included.

Summary: The use of sublingual buprenorphine for chronic pain is off-label. The Division standard for support of off-label use is two positive, prospective, randomized, placebo-controlled studies. The published literature regarding the use of sublingual buprenorphine does not meet this standard with the majority of studies being open-label and/or retrospective. Results are mixed with high incidence of discontinuation due to adverse effects. The use of buprenorphine (Suboxone) for pain will be denied by the Division.

The Substance Abuse and Mental Health Services Administration (SAMHSA) encourages all physicians who are interested in treating opioid dependence – including those who already meet 1 or more of the qualifying criteria – to participate in a DATA 2000 certification program before prescribing Suboxone Film.

Summary: Only those physicians who meet the qualifications according to the Suboxone Sublingual Film website can prescribe Suboxone for the treatment of opioid dependence. This certification is endorsed by the American Academy of Addiction Psychiatry (AAAP), American Osteopathic Academy of Addiction Medicine (AOAAM), American Psychiatric Association



(APA), and American Society of Addiction Medicine (ASAM). A copy of the DATA 2000 certification must be on record with the Division. Qualifications for certification can be found at: www.suboxone.com/hcp/certification/qualifications.aspx

Suboxone will be approved for use in opioid dependence for up to 2 years.

References

1. Adriaensen H, Van De Walle J. Clinical use of buprenorphine in chronic administration. *Acta anaesth.* 1976; 27: 187 – 191.
2. Adriaensen H, Mattelaer B, VanMeenen H. A long-term open, clinical and pharmacokinetic assessment of sublingual buprenorphine in patients suffering from chronic pain. *Acta Anaesth.* 1985, 36, 33-40.
3. Barutell C, Camba A, Conzalez-Escalada JR, et al. High dose transdermal buprenorphine for moderate to severe pain in Spanish pain centres – A retrospective multicenter safety and efficacy study. *Pain Practice.* 2008; 8(5): 355 – 361.
4. Blondell R, Ashrafioun L, Dambra C, et al. A clinical trial comparing tapering doses of buprenorphine with steady doses for chronic pain and coexistent opioid addiction. *J Addict Med* 2010; 4: 140 – 146.
5. Daitch J, Frey M, Silver D, et al. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. *Pain Physician.* 2012; 15: ES59 – ES66.
6. James I, O'Brien C, McDonald C. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine with buprenorphine sublingual tablets in patients with osteoarthritis pain. *Journal of Pain and Symptom Management.* 2010; 40(2): 266 – 278.
7. Malinoff H, Barkin R, Wilson G, et al. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. *American Journal of Therapeutics.* 2005; 12: 379 – 384.
8. Pace MC, Passavanti MB, Grella E, et al. Buprenorphine in long-term control of chronic pain in cancer patients. *Frontiers in bioscience.* 2007; 12: 1291 – 1299.
9. Robbie D. A trial of sublingual buprenorphine in cancer pain. *Br J Clin Pharmac.* 1979; 7: 315S – 317S.
10. Rosenblum A, Cruciani R, Strain E, et al. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: Development and pilot test of a clinical protocol. *Journal of Opioid Management.* 2012; 8(6): 369 – 382.
11. Wolff R, Aune D, Truysers C, et al. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. *Current Medical Research and Opinion.* 2012; 28(5): 833 – 845.

